Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded, Active Comparator-Controlled Phase 3b Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters (Fumaderm Initial/ Fumaderm) for Adult Patients With Moderate to Severe Plaque Psoriasis Who Are Candidates for and Naive to Systemic Treatment
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 May 2017
At a glance
- Drugs Guselkumab (Primary) ; Calcium monoethyl fumarate/dimethyl fumarate/magnesium monoethyl fumarate/zinc monoethyl fumarate
- Indications Psoriasis
- Focus Therapeutic Use
- Acronyms POLARIS
- Sponsors Janssen-Cilag
- 16 May 2017 Planned End Date changed from 13 Feb 2018 to 7 Jun 2018.
- 21 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Dec 2016 Status changed from not yet recruiting to recruiting.